An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Trial Profile

An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Aldoxorubicin (Primary) ; Ifosfamide; Mesna
  • Indications Chondrosarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors CytRx Corporation
  • Most Recent Events

    • 02 Jun 2017 Results (n=27) assessing efficacy and toxicity presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 17 May 2017 Based on the results obtained to date, the company has decided to stop further aldoxorubicin dose escalation and continue to enroll only in the 250mg/m2 cohort.
    • 17 May 2017 According to a CytRx Corporation media release, the data from this and other clinical trials evaluating aldoxorubicin in sarcomas, along with our several other completed clinical and preclinical studies, will form the basis of the planned NDA submission to the US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top